Fortrea Holdings Inc.

Overview

1. "How the company got here" : "Fortrea Holdings Inc. was established in 2023 as an independent, publicly traded company when Labcorp spun off its clinical development business. However, the company's operational roots go back much further, tracing their lineage to the Covance and Labcoat drug development platform, which has decades of experience. This heritage provides Fortrea with established capabilities in clinical development. The company became a standalone entity to focus specifically on contract research services globally. In October 2020, prior to the spin-off, the business that would become Fortrea acquired GlobalCare and snapIoT, companies focused on mobile nursing and digitized clinical platforms, respectively. In February 2023, the business was renamed Fortrea Holdings, and in July 2023, the corporate spin-off from Labcorp was completed." 2. "What it actually does" : "Fortrea operates as a contract research organization (CRO), which means it partners with pharmaceutical, biotechnology, and medical device companies to help them design, conduct, and manage clinical trials. Essentially, Fortrea acts as an outsourced research arm for these companies, managing the complex process of testing new drugs and medical devices. This involves everything from the initial planning and design of studies to patient recruitment, data collection, monitoring, and regulatory submissions. The company's services span the entire clinical development spectrum, from early-phase research (Phase I) to late-stage trials (Phase IV)." 3. "Clinical Services" : "The Clinical Services segment is Fortrea's primary business, encompassing the full spectrum of clinical trial management. This includes planning and executing studies across all phases of development (Phase I-IV), managing clinical pharmacology research (early-stage drug testing in humans), and providing comprehensive clinical development solutions. Companies hire Fortrea to handle study design, site selection, patient recruitment, data management, statistical analysis, and safety monitoring. This segment is the largest contributor to Fortrea's revenue, making up the vast majority of its business." 4. "Enabling Services" : "The Enabling Services segment offers specialized solutions that support the clinical trial process and patient access to therapies. This can include technology-enabled solutions that streamline trial operations and services focused on helping patients access treatments after a drug has been approved. While not as large a portion of the business as Clinical Services, these offerings complement the core trial management activities by providing additional support and expertise." 5. "What management is betting on now" : "Fortrea's management is focused on two main priorities: strengthening its position in the competitive global contract research organization (CRO) market and completing its transition into a fully independent company. This involves improving operational efficiency, enhancing profit margins (the percentage of revenue left after covering costs), and generating stronger cash flow. The company is also strategically expanding its clinical pharmacology capabilities through acquisitions to reduce reliance on external partners and handle larger studies more effectively. Management aims to be the preferred CRO partner for innovative biotech and biopharma companies by focusing on execution, customer fit, and financial improvement."